Global
Q3 sales AUD$1.5 million up 16% on prior comparative period (pcp)
YTD Mar 2026 sales AUD$5.7 million up 7% on prior comparative period (pcp)
Australia
Q3 sales AUD$0.9 million up 15% on prior comparative period (pcp)
YTD Mar 2026 sales AUD$4.2 million up 14% on prior comparative period (pcp)
Canada
Q3 sales AUD$0.1 million up >100% on prior comparative period (pcp)
Q3 sales up 82% on prior quarter; initial sales to Jean Coutu, Quebec
YTD Mar 2026 sales AUD$0.1 million down 65% on prior comparative period (pcp)
USA
Q3 sales AUD$0.5 million up 1% on prior comparative period (pcp)
YTD Mar 2026 sales AUD$1.3 million up 10% on prior comparative period (pcp)
MELBOURNE, Australia, April 17, 2026 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce continued sales growth (unaudited) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract.
Continued Travelan® Q3 sales growth (+15% on pcp) in Australia can be contributed to: (1) increased awareness and consideration driven by extensive digital and social media marketing. (2) same store growth as a result of increased promotion and past promotions driving new customers and return customers respectively; (3) growth from new stores within banner groups in which we secured core ranging in FY25; (4) increased South ...
